Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Biochemical response rate in tumor defined as > 75% decrease in P-MAPK and/or P-AKT
研究概览
简要总结
This phase II trial is studying how well erlotinib works in treating patients with stage I, stage II, or stage IIIA non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib before surgery may shrink the tumor so that it can be removed.
详细描述
PRIMARY OBJECTIVES:
I. To determine the biochemical response rate (> 75% decrease in P-MAPK and/or P-AKT) with daily oral OSI-774 (erlotinib) for 14 consecutive days in patients with early stage, operable NSCLC.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerance of daily oral OSI-774 (erlotinib) as pre-operative treatment for early stage operable NSCLC.
TERTIARY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with suspicion of lung cancer without distant metastases
- •Patients are scheduled to have a tissue diagnostic procedure within 3 to 5 days of pre-registration
- •Patients are willing to allow collection and submission of baseline and post-therapy tumor tissue, skin and blood samples for this study
- •Patients must have ECOG performance status of 0, 1, or 2
- •Patients must have no psychological, familial, sociological, or geographic conditions that will interfere with medical follow-up and compliance with the study protocol
- •Patients must have no prior chemotherapy or radiation therapy or no prior anti- EGFR treatment exposure
- •Patients must be able to take oral medication and not have malabsorption syndrome, or prior gastrointestinal surgery that limits their absorption (i.e. requiring total parental nutrition)
- •Patients must not be using phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, oxcarbazepine, rifapentine, St John's Wort, or any other CYP 3A4 enzyme-inducing agent; any use of these substances must be discontinued at least 2 weeks prior to registration
- •Patients must not be taking any anti-coagulants
- •Patients must not have been treated with a non-approved or investigational drug within 21 days prior to pre-registration; patients must not have serious underlying medical condition that would impair the ability of patient to receive the planned treatment
- •Patients with a known hypersensitivity to OSI-774 (erlotinib) are not eligible
- •Patients must have histologically confirmed NSCLC; cytologic specimens obtained by brushing, washing or needle aspiration of defined lesions will be acceptable
- •Patients must have stage IA (T1N0M0), stage IB (T2N0M0), stage IIA (T1N1M0), stage IIB (T2N1M0; T3N0-1M0), or stage IIIA (T1-3N2M0) disease
- •Patients with small cell component on histology specimen are not eligible
- •A paraffin-embedded cell block and 1-2 segments of frozen tissue demonstrating NSCLC and obtained during the diagnostic biopsy is available for submission
- •Patients must be considered operable candidates and disease must be considered resectable
- •Pregnant or breastfeeding women are excluded from the study because the agents used in this study may be teratogenic to a fetus or child and there is no information on the excretion of the agents or their metabolites into breast milk
- •All females of childbearing potential must have a blood test or urine study within 1 week, prior to registration to rule out pregnancy
- •Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception
- •WBC >= 3500/mm^3
- •ANC >= 1500/mm^3
- •Platelet count >= 100,000/mm^3
- •Total bilirubin < 1.5mg/dL
- •SGPT and SGOT < 3 times institution's upper limit of normal
- •Serum creatinine < 2mg/dl or creatinine clearance >= 20 ml/min
排除标准
- 未提供
研究组 & 干预措施
Treatment (erlotinib)
Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
干预措施: erlotinib hydrochloride (Drug)
Treatment (erlotinib)
Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
干预措施: therapeutic endoscopic surgery (Procedure)
Treatment (erlotinib)
Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Biochemical response rate in tumor defined as > 75% decrease in P-MAPK and/or P-AKT
时间窗: Up to 5 years
次要结局
- Tolerability of erlotinib, graded according to the NCI CTCAE version 3.0(Up to 5 years)